ASH 2022 Conference Coverage
Playback speed
10 seconds
ASH 2022 UK NCRI AML19 Trial: FLAG-Ida With Gemtuzumab Ozogamicin Improves EFS in Younger Patients With Newly Diagnosed AML and Shows an OS Benefit in NPM1- & FLT3-Mutated Subgroups
By
ASH 2022 Conference Coverage
FEATURING
Nigel Russell
By
ASH 2022 Conference Coverage
FEATURING
Nigel Russell
76 views
December 28, 2022
Login to view comments.
Click here to Login
Leukemia